Rocket Corp (RCKT): Price-to-Projected Revenue Ratio
Rocket Pharmaceuticals enjoys a high reputation within the biotechnology community as a responsible leader. A strategic alliance with universities and clinics is accelerating the development of cardiology treatments. Revenues are based on the commercialization of ex vivo therapies for rare blood pathologies. The forward P/S ratio demonstrates the business valuation dynamics, where the level of represents the current value.
Summary analytical data breakdowns for Rocket Corp (RCKT)
- current price and projected stock value:
- stock exchange capitalization data:
- book value of equity indicators:
- debt and solvency information:
Total Debt to Capital Rocket Pharmaceuticals|RCKT - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Rocket Pharmaceuticals|RCKT - Company Cumulative Debt|Debt to Book Value Rocket Corp|RCKT - Company Long-Term Debts|Company Current Liabilities Rocket Pharmaceuticals|Quick Ratio rocketpharma.com
- business earnings and investment ratios data:
RCKT - Net Financial Result|Projected Future Earnings Rocket Pharmaceuticals|RCKT - Price to Earnings Ratio|Forward P/E Multiple Rocket Pharmaceuticals Inc|RCKT - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Rocket Corp|RCKT - Profit before payment of interest, taxes and amortization|Earnings per share for the last twelve months Rocket Pharmaceuticals|RCKT - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months rocketpharma.com|RCKT - Earnings per share increase in current year|Earnings growth forecast for next year Rocket Pharmaceuticals
- sales and revenue data:
Initial company analysis:Rocket Pharmaceuticals, Inc. (RCKT)
To assess the financial stability of Rocket Pharmaceuticals (RCKT), it is critical to track the ratio of current market capitalization to the expected revenue from the commercialization of gene therapy. By analyzing the projected P/S ratio, an investor determines the degree of market optimism regarding the platform's scaling: a sharp upward trend signals a business overvaluation, while stable price action confirms that the company's valuation is adequate relative to its future sales.
Competitors of Rocket Pharmaceuticals
Forward P/S Multiple TEM (Tempus AI, Inc.)|Forward P/S Multiple Qiagen NV QGEN|IONS - Price-to-Projected Revenue Ratio|Forward Price to Sales RGEN (Repligen Inc.)|Avidity Biosciences (RNA) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple crisprtx.com|WGS (GeneDx) - Forward P/S Multiple|Forward P/S Multiple Ultragenyx Pharmaceutical Inc.|Forward P/S Multiple BEAM|Forward Price-to-Revenue Multiple Sarepta Corp SRPT|Forward P/S Multiple TWST (Twist Bioscience)|10xgenomics.com (TXG) - Market Cap to Future Revenue Ratio|NTLA: Forward Price-to-Revenue Multiple|STOK - Forward P/S Multiple|BLFS (BioLife Corp) - Forward Price-to-Revenue Multiple|WVE: Price to Expected Revenue Ratio|MAZE (Maze Therapeutics Inc) - Forward P/S Multiple|sionnatx.com (SION) - Market Cap to Expected Sales Ratio|Forward P/S Multiple PRME|Forward Price-to-Revenue Multiple Taysha Gene Therapies Inc TSHA|Forward P/S Multiple QURE (uniQure Corp)|Forward P/S Multiple MeiraGTx Corp MGTX|RGNX - Price-to-Projected Revenue Ratio|SLDB: Price-to-Projected Revenue Ratio|Ocugen (OCGN) - Price-to-Projected Revenue Ratio|PACB - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Benitec|DSGN: Forward Price to Sales|Forward P/S Multiple FDMT|Forward Price-to-Revenue Multiple lexeotx.com LXEO|Price-to-Projected Revenue Ratio Korro Bio KRRO|Forward P/S Multiple Editas Medicine Inc EDIT|SLN: Forward Price-to-Revenue Multiple|ProQR Therapeutics N.V. - Price to Expected Revenue Ratio|CDXS: Forward P/S Multiple|Market Cap to Projected Revenue SGMO|Price-to-Projected Revenue Ratio Nautilus Biotechnology, Inc.|Market Cap to Projected Revenue MGX (Metagenomi Inc.)|Forward P/S Multiple DTIL|Forward P/S Multiple generationbio.com (GBIO)|Price-to-Projected Revenue Ratio Boundless Bio, Inc. BOLD|Forward Price to Sales XCUR|IMNN - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Phio Pharmaceuticals|MBIO: Forward P/S Multiple|Forward Price-to-Revenue Multiple TransCode Therapeutics, Inc.|Price-to-Projected Revenue Ratio Bionano Genomics Inc.|Forward P/S Multiple adnas.com|Forward P/S Multiple BLUE|IPA - Market Cap to Future Revenue Ratio|Omega - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio OMIC (Singular Genomics Corp)|RGLS: Forward Price-to-Revenue Multiple|Forward Price to Sales SYRS (syros.com)|Telesis Bio (TBIO) - Price-to-Projected Revenue Ratio|Future Price to Revenue TCON (TRACON Pharmaceuticals Inc.)|UBX (Unity Bio) - Forward P/S Multiple
